SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CRISIL Ratings has reaffirmed Sun Pharma's long-term rating at 'Crisil AAA' and short-term rating at 'Crisil A1+'. However, the CRISIL AAA rating has been placed on 'Rating Watch with Developing Implications' due to Sun Pharma's announcement of signing a definitive agreement to acquire Organon & Co. on 27 April 2026. CRISIL will remove the rating from watch after conducting a comprehensive assessment of the acquisition. Separately, ICRA also reaffirmed the company's ratings at '[ICRA]AAA(Stable)' and '[ICRA]A1+' after noting the acquisition announcement.
The reaffirmed AAA ratings reflect Sun Pharma's strong creditworthiness, but the rating watch indicates uncertainty tied to the pending Organon acquisition. The stock may see volatility as investors await clarity on the acquisition's impact to the company's balance sheet.